THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 47 filers reported holding THESEUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,649,584 | -70.4% | 17,713,600 | +2.8% | 1.01% | -65.3% |
| Q2 2023 | $160,790,122 | +5.1% | 17,233,668 | 0.0% | 2.91% | -3.0% |
| Q1 2023 | $153,034,972 | +78.3% | 17,233,668 | 0.0% | 3.00% | +82.9% |
| Q4 2022 | $85,823,667 | -13.2% | 17,233,668 | +1.1% | 1.64% | -10.5% |
| Q3 2022 | $98,842,000 | +4.9% | 17,041,668 | 0.0% | 1.84% | +7.4% |
| Q2 2022 | $94,240,000 | -52.0% | 17,041,668 | 0.0% | 1.71% | -46.4% |
| Q1 2022 | $196,490,000 | -8.0% | 17,041,668 | +1.2% | 3.19% | +16.1% |
| Q4 2021 | $213,514,000 | – | 16,838,668 | – | 2.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 4,108,796 | $11,052,661 | 17.63% |
| Omega Fund Management, LLC | 711,479 | $1,913,879 | 1.76% |
| Lynx1 Capital Management LP | 702,415 | $1,889,496 | 1.25% |
| Orbimed Advisors | 17,713,600 | $47,649,584 | 1.01% |
| Nextech Invest Ltd. | 611,310 | $1,644,424 | 0.50% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $6,047,642 | 0.40% |
| Affinity Asset Advisors, LLC | 400,726 | $1,077,953 | 0.30% |
| DENALI ADVISORS LLC | 127,900 | $344,051 | 0.12% |
| Rock Springs Capital Management LP | 437,329 | $1,176,415 | 0.03% |
| Forefront Analytics, LLC | 17,672 | $47,539 | 0.03% |